# How Long Is the Evidence, Actually?

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/how-long-is-the-evidence-actually

> These are indefinite treatments. In the largest randomized trial at the weight indication, the mean time on the drug was 34.2 months. What the long trials ran for, and what a short evidence base does and does not mean.

## Key points

- SELECT, the largest weight-indication trial: mean drug exposure 34.2 months.
- Exposure and follow-up are different numbers (34.2 vs 39.8) and the larger one gets misquoted as time on the drug.
- No ten-year data exists at the weight dose, because ten years have not passed.
- Unknown is not the same as hidden, and not the same as bad.

These medicines are prescribed as indefinite treatment. Stop and the weight returns; every trial of stopping has found that. So the plan, stated or not, is usually “continue”. How much of that indefinite future has anyone observed? In the largest and longest randomized trial at the weight indication, the mean time participants spent taking the drug was **34.2 months**.[2] That is just under three years.

## What the long trials ran for

*The longest randomized evidence on GLP-1 medicines. Durations copied from each trial's published report. Note what kind of duration each figure is.*

| Trial | Drug and population | Duration |
| --- | --- | --- |
| STEP 5[1] | Semaglutide 2.4 mg, overweight or obesity without diabetes | 104 weeks (2 years) |
| SELECT[2] | Semaglutide 2.4 mg, 17,604 adults with obesity and cardiovascular disease, without diabetes | Mean exposure 34.2 months; mean follow-up 39.8 months |
| SUSTAIN-6[4] | Semaglutide, type 2 diabetes | 104 weeks (2 years) |
| LEADER[3] | Liraglutide, type 2 diabetes | Median follow-up 3.8 years |

> **Exposure and follow-up are not the same number, and the difference matters here.** SELECT followed people for a mean of 39.8 months but they were taking the drug for a mean of 34.2, because people stop and the trial keeps watching. Quoting the follow-up figure as “time on the drug” overstates the drug evidence by more than five months, and it is the commonest way this gets reported.

So the weight-indication evidence runs to roughly two to three years, and for the drugs prescribed for weight, the longest randomized follow-up is about four years: [SURPASS-CVOT](https://glpwatchdog.org/research/tirzepatide-vs-dulaglutide-kidney) followed people on tirzepatide or dulaglutide for a median of 4.0 years, in type 2 diabetes.[5] For a treatment framed as ongoing, that is the whole of what has been watched.

## Why the diabetes trials do not simply fill the gap

GLP-1 medicines have been prescribed in type 2 diabetes far longer than they have for weight, and it is tempting to treat that history as reassurance that covers everything. Partly it does. [LEADER](https://glpwatchdog.org/research/trials/leader) randomized people to liraglutide with a median follow-up of 3.8 years, and it is a real long-duration safety dataset.[3]

But it does not transfer cleanly. Those trials studied a different population, at different doses, for a different purpose. Semaglutide at 2.4 mg for weight is a substantially higher dose than the diabetes trials used, and the people taking it are on average healthier and younger. Reassurance from one setting is worth something in the other; it is not the same as having been measured there.

## What a short evidence base does and does not mean

This is the part that gets distorted in both directions.

- **It does not predict harm.** No signal has emerged at three years that was invisible at one. Nothing here is a reason to expect something to go wrong at year five.
- **It does mean the answer is unknown**, to everyone, including your prescriber and including us. Ten-year data on semaglutide at the weight dose does not exist because ten years have not passed.
- **The comparison is not against certainty.** Living with untreated obesity has its own long-term outcomes, and they are well characterized and not good. A short evidence base on a treatment is not automatically worse than a long evidence base on the alternative.
- **The cardiovascular finding is real and came from the long trial.** In SELECT, a primary cardiovascular event occurred in 6.5% on semaglutide against 8.0% on placebo.[2] Long trials are how benefits of that kind get found at all.

> What happens at ten years is unknown to everyone, because ten years have not passed.

## What this means for your decision

The practical consequence is not “do not take it”. It is that the indefinite part of indefinite treatment should be a conversation, held early, with someone who knows your history, rather than something you discover at the point where the supply or the money stops.

Two things follow from that. First, whether you can keep getting it is a clinical question and not only a financial one, because stopping has a predictable result: our [what happens when you stop](https://glpwatchdog.org/research/what-happens-when-you-stop-a-glp1) covers the trial evidence, and the [price tracker](https://glpwatchdog.org/price-tracker) keeps a dated figure for every seller we follow. Second, being on a treatment whose [long-term record](https://glpwatchdog.org/research/lists/top-glp1-long-term-safety-studies) is still being written is a reason for ordinary monitoring, not alarm.

> New readouts keep arriving. Extension studies and outcome trials in kidney disease, heart failure and liver disease are steadily lengthening the record. Our [trial tracker](https://glpwatchdog.org/research/trials) follows what is running and what has reported.

## Frequently asked questions

### How long have GLP-1 drugs been studied for weight loss?

The randomized evidence at the weight indication runs to roughly two to three years. STEP 5 ran 104 weeks. SELECT, the largest, had a mean drug exposure of 34.2 months and a mean follow-up of 39.8 months across 17,604 people.

### Is there ten-year data?

Not at the weight-management dose, because ten years have not passed since it came into use. For the drugs prescribed for weight, the longest randomized follow-up is about four years: LEADER ran a median 3.8 years on liraglutide and SURPASS-CVOT a median 4.0 years on tirzepatide, both in type 2 diabetes.

### Do the diabetes trials cover the gap?

Partly, and not cleanly. They studied a different population at different doses for a different purpose; semaglutide 2.4 mg for weight is a higher dose than the diabetes trials used. That history is real reassurance, but it is not the same as having been measured in this setting.

### Does a short evidence base mean the drug is unsafe long term?

No. It means the answer is unknown rather than concealed, and no signal has appeared at three years that was invisible at one. And the comparison is not against certainty: untreated obesity has its own well-characterized long-term outcomes.

### What is the difference between exposure and follow-up?

Exposure is time spent taking the drug; follow-up is time the trial kept watching, including after people stopped. In SELECT those were 34.2 and 39.8 months. Reporting the follow-up figure as time on the drug overstates the evidence by more than five months, and it happens often.

## References

1. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022. PMID: 36216945. https://pubmed.ncbi.nlm.nih.gov/36216945/
2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023. PMID: 37952131. https://pubmed.ncbi.nlm.nih.gov/37952131/
3. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016. PMID: 27295427. https://pubmed.ncbi.nlm.nih.gov/27295427/
4. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016. PMID: 27633186. https://pubmed.ncbi.nlm.nih.gov/27633186/
5. Zoungas S, D'Alessio D, Pavo I, et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified analysis of SURPASS-CVOT. The Lancet Diabetes & Endocrinology. 2026. PMID: 42114520. https://pubmed.ncbi.nlm.nih.gov/42114520/

---

Cite as: GLP Watchdog, Nora Bissett, "How Long Is the Evidence, Actually?", published 2026-08-19, updated 2026-10-27. https://glpwatchdog.org/research/how-long-is-the-evidence-actually

Canonical HTML page: https://glpwatchdog.org/research/how-long-is-the-evidence-actually

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
